Recital 7, Regulation (EU) 2024/2699

In forcesince 18 Oct 2024

Regulation (EU) 2021/2282 provides for the involvement of patients, clinical experts and other relevant experts (‘individual experts’) having expertise in the therapeutic area concerned in joint clinical assessments and joint scientific consultations. Similarly, individual patients and healthcare professionals having expertise in the therapeutic area concerned are being engaged by the European Medicines Agency in the context of the evaluation of medicinal products. Joint clinical assessments and joint scientific consultations under Regulation (EU) 2021/2282 are conducted on the health technologies that are subject to the centralised procedure provided for under Regulation (EC) No 726/2004 of the European Parliament and of the Council [Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (OJ L 136, 30.4.2004, p. 1, ELI: http://data.europa.eu/eli/reg/2004/726/oj).], the clinical evaluation consultation procedure pursuant to Article 54 of Regulation (EU) 2017/745 and the performance evaluation consultation procedure pursuant to Article 48(6) of Regulation (EU) 2017/746 of the European Parliament and of the Council [Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices and repealing Directive 98/79/EC and Commission Decision 2010/227/EU (OJ L 117, 5.5.2017, p. 176, ELI: http://data.europa.eu/eli/reg/2017/746/oj).]. Under Regulation (EU) 2021/2282, the joint clinical assessments are to be conducted in parallel with the centralised procedure and in close cooperation with the European Medicines Agency and joint scientific consultations may be conducted in parallel with the preparation of scientific advice pursuant to Article 57(1), point (n), of Regulation (EC) No 726/2004 and with the consultation with an expert panel pursuant to Article 61(2) of Regulation (EU) 2017/745 and in close cooperation with the European Medicines Agency. Therefore, the HTA secretariat and the European Medicines Agency should cooperate to identify individual experts to be engaged in the respective procedures.